| Literature DB >> 17659340 |
Rebekah L Browning1, Susan M Geyer, Amy J Johnson, Diane F Jelinek, Renee C Tschumper, Timothy G Call, Tait D Shanafelt, Clive S Zent, Nancy D Bone, Gordon W Dewald, Thomas S Lin, Nyla A Heerema, Michael R Grever, Neil E Kay, John C Byrd, David M Lucas.
Abstract
TCL-1 expression is variable in CLL, and no study has examined its association with treatment response. We measured TCL-1 protein in CLL cells from 51 patients who then received pentostatin, cyclophosphamide, and rituximab. TCL-1 expression did not correlate with any pre-treatment characteristics. Lower TCL-1 levels were associated with higher probability of attaining flow cytometry-negative status post-treatment (52% versus 17%, p=0.046). Trends toward improved complete remission rate (49% versus 19%, p=0.064) and progression-free survival (medians: 33 versus 20 months, p=0.199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17659340 PMCID： PMC2225453 DOI： 10.1016/j.leukres.2007.05.020
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156